The Role of Proton Pump Inhibitors in the Treatment of Barrett’s Esophagus
Barrett’s esophagus (BE), as a more frequent complication of gastroesophageal reflux disease, is a metaplastic condition in which the normal squamous epithelium of the esophagus is replaced by specialized intestinal metaplastic epithelium, and that, in about 10% of patients with gastroesophageal ref...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2023
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/87005 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Barrett’s esophagus (BE), as a more frequent complication of gastroesophageal reflux disease, is a metaplastic condition in which the normal squamous epithelium of the esophagus is replaced by specialized intestinal metaplastic epithelium, and that, in about 10% of patients with gastroesophageal reflux disease (GERD) and the main condition for dysplasia and adenocarcinoma. The incidence of adenocarcinoma of the cardia is rapidly increasing at a rate that exceeds that of any other cancer. Recently, acid suppression with proton pump inhibitors (PPIs) has become the cornerstone of treatment for patients with BE. Many worldwide investigations showed that PPI is effective in the regression of BE with low-grade dysplasia and especially for the regression of intestinal metaplasia, incomplete or complete, for long-term use of these medicaments. This chapter reviews the specific endpoints of such treatment, included and our results for this dilemma. |
|---|---|
| ISBN: | 978-1-80355-957-5 |
| DOI: | 10.5772/intechopen.111394 |